You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Mallinckrodt
Dow
Express Scripts
Harvard Business School

Last Updated: October 26, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,192,719

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,192,719 protect, and when does it expire?

Patent 8,192,719 protects MACRILEN and is included in one NDA.

This patent has eleven patent family members in ten countries.

Summary for Patent: 8,192,719
Title:Methods and kits to diagnose growth hormone deficiency by oral administration of EP 1572 or EP 1573 compounds
Abstract: A method of assessing growth hormone deficiency in a human or animal subject, the method comprising administering orally to the subject EP 1572 (Formula I) or EP 1573 (Formula II), obtaining a post-administration sample from the subject, determining the level of growth hormone in the sample and assessing whether the level of growth hormone in the sample is indicative of growth hormone deficiency in the subject. Preferably, the GH level in the sample is measured by immunoassay. Also disclosed is a kit of parts constituting a diagnostic kit comprising: (a) EP 1572 or EP 1573 formulated for oral administration; and (b) means for determining the level of growth hormone in a sample.
Inventor(s): Larsen; Finn (Edinburgh, GB)
Assignee: Aeterna Zentaris GmbH (Frankfurt, DE)
Application Number:12/279,805
Patent Claim Types:
see list of patent claims
Use; Device; Dosage form;

Drugs Protected by US Patent 8,192,719

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novo MACRILEN macimorelin acetate FOR SOLUTION;ORAL 205598-001 Dec 20, 2017 RX Yes Yes   Start Trial   Start Trial A METHOD FOR THE DIAGNOSIS OF ADULT GROWTH HORMONE DEFICIENCY BY MEASURING THE LEVEL OF GROWTH HORMONE AFTER ORAL ADMINISTRATION OF MACIMORELIN   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,192,719

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0603295.7Feb 18, 2006
PCT Information
PCT FiledFebruary 19, 2007PCT Application Number:PCT/GB2007/000566
PCT Publication Date:August 23, 2007PCT Publication Number: WO2007/093820

International Family Members for US Patent 8,192,719

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Cyprus 1115080   Start Trial
Denmark 1984744   Start Trial
European Patent Office 1984744   Start Trial
Spain 2404582   Start Trial
United Kingdom 0603295   Start Trial
Japan 2009526989   Start Trial
Japan 4852728   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Colorcon
AstraZeneca
Baxter
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.